Health Technology Assessment
September 14, 2023 - We are thrilled to announce a groundbreaking collaboration between MORSE Consulting and Medlior Health Outcomes Research, two leaders in the Canadian pharmaceutical market access landscape. This partnership aims to blend MORSE Consulting's unparalleled expertise in payer and HTA strategies with Medlior's cutting-edge real-world evidence solutions, offering our clients an unmatched array of services to navigate the complex world of pharmaceutical market access. MORSE Consulting is a…
Author: Patrick Manfred, Vice-President, TACT Conseil, Quebec Market Access Expert Date: June 2, 2021 A proposal to modify the current regulation framing the fees payable to the Institut national d'excellence en santé (INESSS) to complete a scientific evaluation of a drug and/or a stable blood product was published in Part 2 of the Quebec Official Gazette, on March 18, 2021. If the Quebec government does not deviate from…
HTA Panel – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
Panel 3: Health Technology Assessment Panel Description: Canada’s centralized HTA agency, CADTH, has recently released a new 3-year strategic plan that marks a shift from its previous vision. Noteworthy is the focus of recommendations on alignment of drug assessment with the priorities of the participating plans over all phases of the technology life cycle. Join us to hear CADTH describe their new strategic plan, how their mandate has evolved,…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
Health Technology Assessment - Info and details on - MORSE Consulting Inc.
